In West Africa, Lassa fever remains a persistent and recurring health threat, causing hundreds of lives each year and underscoring urgent need for sustained investment in research and vaccine ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Therapeutic advances have altered the neurodegenerative trajectory and improved clinical outcomes for individuals with spinal muscular atrophy. Current therapies increase concentrations of survival ...

Medicine has traditionally relied on a pathophysiology-to-phenotype paradigm, whereby specific pathological processes are linked to signs and symptoms. This paradigm maintains that complex systems are ...

Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test ...

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Prote ...

Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...